News Search Results
Jul 23, 2025, 06:00 ET Theravance Biopharma to Participate in an Upcoming Investor Conference
July 23, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/
More news about: Theravance Biopharma, Inc.
Jul 23, 2025, 05:00 ET Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9
More news about: Trailhead Biosystems Inc
Jul 22, 2025, 17:31 ET ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight
HNSCC companies, including Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, among
More news about: DelveInsight Business Research, LLP
Jul 22, 2025, 15:32 ET Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
July 21, 2025, and the matter is now closed. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Jul 22, 2025, 10:21 ET Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
tissues and organs affected by these neurologic and neuromuscular diseases." About AAVnerGene, Inc. AAVnerGene is a creativity-powered biotechnology company pioneering next-generation AAV vector technologies. The company's proprietary platforms include AAVone, a high-yield, single-plasmid
More news about: Klotho Neurosciences, Inc.
Jul 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers - FTRE
global contract research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. The Company claims to have the "scale and expertise to advise, design and deliver [its] customers' programs, projects
More news about: Pomerantz LLP
Jul 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Jul 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Jul 22, 2025, 09:15 ET OrbiMed Promotes Mona Ashiya to General Partner
is a recognized leader in biotechnology investing," OrbiMed Managing Partner Carl Gordon said. "She has made significant contributions to the industry and to OrbiMed. We look forward to continuing to work with her to start and grow the next generation of exciting biotechnology companies." Since
More news about: OrbiMed
Jul 22, 2025, 09:00 ET Hatch.Bio Labs Introduces Advanced Vivarium Facility Following Successful Site Launch
Biotechnology and life sciences companies face unique operational and logistical challenges as they scale, which can distract them from the development of impactful
More news about: Hatch.Bio Labs
Jul 22, 2025, 09:00 ET BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call. About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Jul 22, 2025, 08:45 ET Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas, Chief Executive Officer (CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova),
More news about: MarketNewsUpdates
Jul 22, 2025, 08:42 ET Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, updates today that in a live broadcast, NeuroSense CEO Alon
More news about: NeuroSense
Jul 22, 2025, 08:30 ET Halozyme to Report Second Quarter 2025 Financial and Operating Results
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Jul 22, 2025, 08:00 ET Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. About Whitehawk Therapeutics Whitehawk Therapeutics is an oncology therapeutics
More news about: Whitehawk Therapeutics, Inc.
Jul 22, 2025, 08:00 ET Codagenix Awarded PATH Subcontract to Develop Stabilized Novel Oral Polio Vaccine Candidates
N.Y., July 22, 2025 /PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company, today announced a collaboration agreement with PATH funded by a grant from the Gates Foundation to apply its proprietary synthetic biology
More news about: Codagenix Inc.
Jul 22, 2025, 08:00 ET Avant Technologies' Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference
("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas, Chief Executive Officer (CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova),
More news about: Avant Technologies Inc.
Jul 22, 2025, 08:00 ET Diakonos Oncology Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating DOC1021 (dubodencel) for Glioblastoma
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced that the first patient has been
More news about: Diakonos Oncology
Jul 22, 2025, 08:00 ET A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US
Medical Limited About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company in the late clinical stages of development for Xanamem® (emestedastat), its novel oral therapy for Alzheimer's disease and depression. The
More news about: Actinogen Medical Limited
Jul 22, 2025, 07:34 ET Nikko AM Introduces ChiNext ETF on Singapore Exchange under ETF Link, Tied to E Fund's Onshore ETF
(SZSE). Over 90% of the index is weighted in strategic emerging industries such as next-generation information technology, new energy vehicles, and biotechnology, and includes leading companies like CATL, Inovance, InnoLight, Mindray, and Sungrow. The index constituents have demonstrated strong fundamentals,
More news about: E Fund Management
Jul 22, 2025, 07:00 ET Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene therapies for patients suffering vision loss from retinal degenerative diseases,
More news about: Nanoscope Therapeutics
Jul 22, 2025, 06:00 ET Exyte receives Facility Diamond Partner Award for CATL Battery Cell Gigafactory in Germany
developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of complete solutions with the highest standards
More news about: Exyte
Jul 22, 2025, 06:00 ET Danaher Reports Second Quarter 2025 Results
three and six-month periods ended June 27, 2025 ($432 million pretax as reported in this line item, $328 million after-tax) and a facility in the Biotechnology segment recorded in the six-month period ended June 27, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).
More news about: Danaher Corporation
Jul 22, 2025, 03:52 ET METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting
nonprofit scientific organization dedicated to advanced drug delivery. At this year's meeting, METiS Technologies stood out as the only Chinese biotechnology company participating with a featured poster presentation. Dr. Hongming Chen, Co-founder and Chief R&D Officer
More news about: METiS Technologies
Jul 22, 2025, 03:00 ET SkylineDx's Merlin Melanoma Assay shows its ability to reduce SLNB by over 40% in a Danish Multicenter Validation Study
www.merlinmelanomatest.com. About SkylineDx SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx